Ay, S. Et Al. 2022. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. JOURNAL OF CHEMOTHERAPY , vol.34, no.7 , 465-471.

Ay, S., Atci, M. M., Arikan, R., Dulgar, O., Ozyukseler, D. T., Paksoy, N., ... DOĞAN, İ.(2022). FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. JOURNAL OF CHEMOTHERAPY , vol.34, no.7, 465-471.

Ay, Seval Et Al. "FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer," JOURNAL OF CHEMOTHERAPY , vol.34, no.7, 465-471, 2022

Ay, Seval Et Al. "FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer." JOURNAL OF CHEMOTHERAPY , vol.34, no.7, pp.465-471, 2022

Ay, S. Et Al. (2022) . "FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer." JOURNAL OF CHEMOTHERAPY , vol.34, no.7, pp.465-471.

@article{article, author={Seval Ay Et Al. }, title={FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer}, journal={JOURNAL OF CHEMOTHERAPY}, year=2022, pages={465-471} }